Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S
Go back to Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S| TONIX PHARM HLDG (NASDAQ: TNXP) | Delayed: 11.14 -0.28 (2.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.42 | 52 Week High | $7.95 | |||
| Open | $11.43 | 52 Week Low | $0.40 | |||
| Day High | $11.47 | P/E | N/A | |||
| Day Low | $11.09 | EPS | $-5.33 | |||
| Volume | 177,049 | |||||
